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Mutations in BRCA1 and BRCA2 genes may cause defect-
ive DNA repair and increase the risk for breast cancer.
Folate deficiency is associated with increased breast cancer
risk and induces chromosome abnormalities. We hypothes-
ized that BRCA1 and BRCA2 germline mutation carriers
are more sensitive to the genome damaging effect of folate
deficiency compared with healthy non-carrier controls and
that this sensitivity is further increased in those carriers
who develop breast cancer. We tested these hypotheses in
lymphocytes cultured in amedium containing 12 or 120 nM
folic acid (FA) for 9 days and measured proliferative capa-
city and chromosomal instability using the cytokinesis-
block micronucleus assay. BRCA1 and BRCA2 mutation
carriers with or without breast cancer were not abnor-
mally sensitive to FA deficiency-induced chromosome
instability; however, BRCA2 mutation carriers had signi-
ficantly reduced cell proliferation. FA deficiency reduced
cell proliferation and increased micronucleus formation
significantly, accounting for 45–59% and 70–75% of the
variance in these parameters compared with 0.3–8.5% and
0.2–0.3% contributed by BRCA1 or BRCA2 mutation car-
rier status, respectively. The results of this study suggest
that moderate folate deficiency has a stronger effect on
chromosomal instability than BRCA1 or BRCA2mutations
found in breast cancer families.
Introduction
Folate, a B-vitamin found in a wide variety of plant foods, is
required for the synthesis of dTMP from dUMP, methionine
and ultimately S-adenosylmethionine, the primary methyl
donor required for methylation at CpG sequences in DNA.
Folate deficiency causes DNA hypomethylation and alters
both gene expression and chromatin structure, all of which
are considered initiating events in several malignancies
(1–4). In addition, folate deficiency reduces dTMP synthesis
and consequently increases uracil incorporation into DNA,
which may result in the generation of single- and double-strand
breaks, chromosome aberrations and micronuclei (5–9).
Reduced dTMP synthesis is also associated with folate-
sensitive fragile sites expression (1), which has been suggested
to be involved in carcinogenesis (10).
Breast cancer is the most common malignancy affecting
women in developed countries (11,12) (www.dep-iarc.fr).
Besides a history of familial breast cancer, age at menarche,
age of first full-time pregnancy and lifestyle factors such as
socioeconomic status and diet are important factors in the
development of breast cancer. Excessive alcohol consumption
(13) has been reported to be a breast cancer risk factor,
whereas a diet rich in vitamins A, C, E, B12 and folate may
have a protective effect (14–22).
Approximately 5–10% of all breast cancer cases are
considered to be hereditary. Hereditary breast cancer, usually
characterized by its early onset, has been linked to the BRCA1
and BRCA2 germline mutation (23). BRCA1, mapped to chro-
mosome 17q21 (24–26), and BRCA2, mapped to 13q12–q13,
(27) code for important proteins required for genome stability
maintenance because of their functions in cell cycle check-
point control, ubiquitylation, mitotic spindle formation, tran-
scriptional regulation and DNA repair. BRCA1 and BRCA2 are
involved in homologous recombination repair, whereas
BRCA1 is also involved in non-homologous end joining and
nucleotide excision repair (especially transcription-coupled
repair of oxidative damage) (28–31).
Peripheral blood lymphocytes from BRCA1 and BRCA2
carriers (with or without breast cancer) show enhanced sensit-
ivity to micronucleus induction by a wide variety of clastogens
compared with controls (32,33). Folate deficiency has been
shown to mimic ionizing radiation in damaging DNA by
inducing single- and double-strand breaks and micronuclei
(34–37). It is therefore plausible that cells exhibiting an
impaired single- and/or double-strand break repair system
may be more sensitive to the chromosome damaging effects
of folate deficiency. Therefore, we hypothesized that cells with
an inactivating mutation in BRCA1 or BRCA2 are more sus-
ceptible than non-mutant controls to the genome damaging
effect of folic acid (FA) deficiency, and that this effect is
greater in cells of BRCA1 or BRCA2 carriers who developed
breast cancer compared with those carriers who are breast
cancer free.
The model used to test these hypotheses consisted of 9-day
cultures, in folate replete or deficient medium, of human peri-
pheral lymphocytes from BRCA1 or BRCA2 germline muta-
tion carriers, with or without breast cancer, and non-carrier
relatives, and the cytokinesis-block micronucleus (CBMN)
assay. In its comprehensive mode the CBMN-assay can be
used to measure micronuclei (biomarkers of chromosome
breakage and loss), nucleoplasmic bridges (biomarker of
asymmetrical chromosome rearrangements and DNA
mis-repair), nuclear buds (biomarker of gene amplification),
Abbreviations: BMI, body mass index; FA, folic acid; MNed BNC,
binucleated cell containing micronuclei; NBud BNC, binucleated cell
containing nuclear buds; NDI, nuclear division index; Npb BNC,
binucleated cell containing nucleoplasmic bridges.
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necrosis and apoptosis (biomarkers of cell death), and nuclear
division index (NDI) (biomarker of mitogen responsiveness
in lymphocytes and/or cytostatic effect) (7). Additionally, in
combination with the long-term cultures of lymphocytes,
viable cell growth was also measured over 9 days. This model
has previously been used to demonstrate the genome damaging
effect of moderate folate deficiency and the modulating effect
of the MTHFR C677T polymorphism and riboflavin concen-
tration on sensitivity to folate deficiency-induced genome
damage (34).
Materials and methods
Approval for this study was obtained from the Human Experimental Ethics
committees of CSIRO Health Sciences and Nutrition, University of South
Australia and Women’s and Children’s Hospital in Adelaide, South Australia.
A total of 66 female volunteers were recruited from a database of breast cancer
families who had previously undergone BRCA1 or BRCA2 gene mutation
testing at the South Australian Clinical Genetics Service. We recruited 8–15
participants for each of the following groups amongst BRCA1 or BRCA2
breast cancer families: (i) controls, (ii) mutation carriers without breast cancer,
(iii) mutation carriers with breast cancer. Controls were non-carrier relatives of
BRCA1 or BRCA2 mutation carriers and had no history of breast cancer. All
participants with breast cancer completed chemotherapy and/or radiotherapy
6 months prior to blood sample collection with the exception of one participant
who completed treatment 1 month before blood collection. Volunteer age and
body mass index (BMI) and the specific mutations in BRCA1 and BRCA2
mutation carriers are listed in Tables I and II, respectively. With one exception,
the BRCA1 and BRCA2 mutations in the carriers were pathogenic and place a
woman at high risk of developing breast cancer. There is uncertainty about
the pathogenicity of the 4486G4T variant in BRCA2 (38); two women in the
study carried this variant, one having had breast cancer and the other being
unaffected. The controls were at 25–50% risk of having the pathogenic
mutation which had been documented in another relative. They were only
tested for that mutation and were not screened for mutations elsewhere in the
BRCA1 or BRCA2 genes. The frequency of BRCA mutations in the general
population is low (1:1000) and mutation screening was not pursued in
non-carriers of the family’s mutation. Lymphocytes were isolated from
heparinized blood samples using Ficoll-Paque gradients (Amersham
Biosciences, Adelaide, Australia) and cultured, in duplicate, in 1 ml of
RPMI-1640 without FA containing 10% dialysed foetal bovine serum (Trace
Scientific, Melbourne, Australia), 2 mM L-glutamine (Sigma, Sydney, Austra-
lia), 1% penicillin (5000 IU/ml)/streptomycin (5 mg/ml) solution (Trace Sci-
entific) and either 12 or 120 nM FA (Sigma). The FA deficiency concentration
chosen (12 nM) is the lowest possible that allows cell growth, maximizes
induced chromosomal damage and is within the physiological range normally
seen in blood of folate deficient individuals. The long-term culture procedure,
summarized in Figure 1, was performed as described by Crott et al. (39) with
minor modifications. In brief, cultures were set up at 1.0  106 cells/ml in 10
ml sterile conical tubes (Technoplas, Adelaide, Australia), stimulated to divide
with phytohaemagglutinin (PHA; 30 mg/ml; Murex Biotech, Kent, England),
and then incubated at 37C and 5% CO2 in a humidified atmosphere for 9 days.
Culture medium was replaced with fresh medium 3 and 6 days after mitogen
stimulation. Before changing the culture medium, cell number and viability
were determined using a Coulter counter (Coulter Electronics, Hertfordshire
UK) and Trypan Blue exclusion (Sigma), respectively. After gentle spinning
(125 g for 10 min), a 50 ml aliquot of the supernatant was removed from each
culture and transferred to a new sterile culture tube. The remaining supernatant
was discarded and the cell pellet resuspended in 500 ml of the appropriate fresh
culture medium. A second cell count was performed to calculate the volume of
cell solution needed to set up the fresh cultures at 0.5  106 viable cells/ml.
Fresh medium and 10 units of interleukin-2 (Roche Diagnostics, Basel,
Switzerland) were added to the culture tubes with the supernatant aliquot.
On day 9, cell number and viability were also determined. The extent
of viable cell growth was determined using the starting concentrations on
day 0, 3 and 6, and the concentration of viable cells on days 3, 6 and 9. Only
cell counts for day 9 are shown because this figure is based on the estimated
results from growth curves generated from the viable cell counts on days
3, 6 and 9.












N 15 8 12 9 12 10
Age (years) 57.5  3.5c 41.8  3.5a 51.4  3.2b 54.6  3.0 48.6  4.4 50.5  3.7
BMI (kg/m2)# 27.3  1.1d 25.3  1.3d 30.1  1.9e 28.0  1.4 27.9  1.3 27.7  1.7
Groups that do not share the same superscript letter within a row are significantly different from each other (P 5 0.05).
One-way ANOVA P 5 0.001.
#One-way ANOVA P ¼ 0.002.
Table II. Description and distribution of BRCA1 and BRCA2 mutations amongst carriers with or without cancer
BRCA1 BRCA2
n Without breast cancer n With breast cancer n Without breast cancer n With breast cancer
3 300 T4G (C61G)a 1 188del11 (39X) 1 IVS4-12del5 3 2988delC (959X)e
2 3717 C4T (Q1200X)b 1 300 T4G (C61G) 1 2988delC (959X)e 1 3031 G4A (D935N)f
1 IVS18þ1G4T 1 1294del40 (397X) 1 3031 G4A (D935N)f 1 4486 G4T (D1420Y)g
1 exon13dup (1460X)c 1 3717 C4T (Q1200X)b 1 4075delGT (1284X) 1 6024delTA (1943X)
1 IVS4-1 G4T d 1 3988delAA (1293X) 1 4486 G4T (D1420Y)g 1 6468insA (STOP2084)
2 4184-4187delTCAA (N1364X) 1 4706delAAAG (1502X) 1 7180 C4T (R2318X)
2 5385insC (1829X) 1 5910 C4G (Y1894X) 1 9161 C4A (S2978X)
1 exon13dup (1460X)c 1 8034insAG (2648X) 1 IVS7-1 G4A
2 IVS4-1 G4Td 1 8205-1 G4C
1 8714 A4G (del exon 19)
1 9132delC (2975X)
1 IVS7-1 G4A
Individuals or groups sharing the same superscript letter are members of the same family.
S.Beetstra et al.
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To perform the CBMN-assay cytochalasin-B (4.5 mg/ml; Sigma) was added
to the cultures 8 days after PHA stimulation, and 24 h later the cells were
transferred onto microscope slides using a cyto-centrifuge (Shandon Southern
Products, Cheshire, UK). Slides were then air dried, fixed and stained using
Diff-Quik (LabAids, Narrabeen Australia). Coded slides were examined by
one person at 1000 magnification using a light microscope. A total of
250 cells were scored for each duplicate culture (total of 500 cells) to deter-
mine the ratios of mononucleated-, binucleated-, multinucleated-, apoptotic
and necrotic cells and to calculate the NDI (40). Binucleated cells (BNCs)
containing micronuclei (MNed BNCs), nucleoplasmic bridges (Npb BNCs)
and nuclear buds (NBud BNCs) were scored in at least 500 BNCs per duplicate
slide (total 1000 BNCs). The slides were scored using the scoring criteria as
described by Fenech (40) and Fenech et al. (41).
Statistics
The study was designed to detect an increase of at least 6 MNed BNCs per
1000 BNCs, which is equivalent to the amount induced by 0.10 Gy of X-rays, a
biologically relevant dose that is 100 times the annual radiation exposure
limit for the general public (6). Based on an observedmean value of 11.4MNed
BNCs per 1000 BNCs and a SD of 4.1 in our previous study (34), it was
estimated that it should be possible to detect an increase of 6 MNed BNCs per
1000 BNCs with 9 subjects per group with 80% power and a P value of 0.05.
Pearson correlation and regression analysis were used to determine the
relationships between biomarkers and age or BMI. When a significant correla-
tion was observed the relevant biomarker was adjusted for age and/or BMI. For
adjustment the following formula were used: (i) for age: Y51.7y¼ (51.7 X)Sþ
M and (ii) for BMI: Y27.9 ¼ (27.9 X)S þM, where X ¼ actual age in years, S
¼ slope of the regression line for the relationship between age and the
biomarker, M ¼ actual value measured, Y51.7y ¼ biomarker adjusted to the
value expected at age 51.7 years (average age of all study subjects) and Y27.9¼
biomarker adjusted to the value expected for a BMI of 27.9 (average BMI of
all study subjects). One-way ANOVA, followed by Tukey’s post hoc multiple
comparison test, was used to compare controls, mutation carriers without
cancer and mutation carriers with cancer. Paired t-test (two-tailed) was used
to compare the effect of low and high FA on various biomarkers. To estimate
the relative sensitivity to the effects of FA deficiency we subtracted the values
for 120 nM FA cultures from those for corresponding 12 nM FA cultures and
compared results across groups using one-way ANOVA. Two-way ANOVA
was used to determine the percentage of the variance in the biomarkers
measured and any interactive effects attributable to FA concentration and
mutation carrier status or FA and breast cancer status in the BRCA1 and
BRCA2 groups. All data are expressed as mean  SEM. Significance was
accepted at P 5 0.05. Two-way ANOVA statistical analysis was performed
using GraphPad Prism 4.00 (GraphPad, San Diego, CA). All other statistical
analyses were performed using SPSS 11.5 (SPSS, Chicago, IL).
Results
Volunteer age and BMI
Age and BMI of participants are displayed in Table I, and
BRCA1 and BRCA2 mutations in carriers are presented in
Table II. The BRCA1 subgroups differed significantly in age
(P 5 0.01). Additionally, the BMI of BRCA1 carriers with
breast cancer was significantly higher compared with BRCA1
controls and carriers without breast cancer (P ¼ 0.002). Age
and BMI did not differ significantly among the BRCA2 sub-
groups. The average age and BMI in the BRCA1 study group
was not significantly different compared with the BRCA2
study group. Age was significantly correlated with viable cell
growth on day 9, percentage of necrotic cells, NDI and NBud
BNCs, while BMI was significantly correlated with viable cell
growth on day 9 and percentage of necrotic cells only
(Table III).
Effect of FA concentration and BRCA1 or BRCA2 carrier- and
breast-cancer status on viable cell growth and CBMN-assay
biomarkers
Viable cell growth data are shown in Figure 2. Results for
CBMN-assay biomarkers and one-way ANOVA analysis are
shown in Table IV. Two-way ANOVA analysis results for all
data are shown in Table V.
Viable cell growth
Cell growth did not significantly differ between BRCA1
mutation carriers (with or without breast cancer) and BRCA1
controls under both low and high FA conditions. However,
BRCA2 mutation carriers with breast cancer had significantly
lower viable cell growth compared with BRCA2 controls in
both 12 and 120 nM FA cultures (P ¼ 0.001 and 0.021,
respectively); the percentage by which viable cell growth
was induced in 120 nM relative to 12 nM FA was not signi-
ficantly different in mutation carriers compared with controls
(data not shown). Two-way ANOVA revealed a significant
Start 
culture




DAY0 3 6 8 9
Fig. 1. Experimental design showing the days when cell counts and viabilities, subcultures and CBMN-assay were performed. Cells were initiated at 1.0 
106 cells/ml and subcultured on day 3 and day 6 to a concentration of 0.5  106 cells/ml. In the CBMN-assay, cytochalasin-B was added on day 8 and cells
were harvested on day 9.
Table III. Pearson correlation matrix
[FA] in medium (nM) Viable cell growth (day 9) NDI % Apoptotic % Necrotic MNed BNCs Npb BNCs NBud BNCs
Age 12 r 0.184 0.131 0.048 0.162 0.028 0.027 0.274
120 r 0.257 0.258 0.112 0.015 0.042 0.050 0.124
BMI 12 r 0.153 0.047 0.011 0.200 0.032 0.080 0.024
120 r 0.056 0.005 0.046 0.006 0.031 0.035 0.045
Correlation is significant at the 0.05 level (two-tailed).
Correlation is significant at the 0.01 level (two-tailed).





























































































































Fig. 2. Viable cell growth of peripheral lymphocytes from BRCA1 and BRCA2 carriers with or without breast cancer and non-carrier controls, on day 9 in
media containing 12 or 120 nM FA. Cultures were initiated at 1.0  106 cells/ml and subcultured at 0.5  106 cells/ml on day 3 and day 6. Grey bars
represent the viable cell growth in 12 nM FA, black bars the viable cell growth in 120 nM FA. Bars that do not share the same letter are significantly different
from each other (P50.05). Data shown were adjusted for the effect of age and BMI.
Table IV. Experimental data for BRCA1 and BRCA2







NDI 12 nM 1.29  0.01a 1.27  0.02a,b 1.24  0.02b 0.039
120 nM 1.40  0.02a 1.31  0.03b 1.37  0.03a,b 0.047
t-test P 50.001 NS 50.001
% Apoptotic 12 nM 14.6  0.8a 14.3  0.9a 14.0  0.6a NS
120 nM 14.7  0.7a 14.8  0.8a 15.7  1.0a NS
t-test P NS NS NS
% Necrotic 12 nM 12.7  0.8a 13.3  0.9a 11.2  0.9a NS
120 nM 11.2  0.8a 11.4  1.0a 9.5  0.7a NS
t-test P NS 0.050 NS
MNed BNCs 12 nM 17.4  0.8a 17.2  1.3a 17.9  1.0a NS
120 nM 7.8  0.4a 8.3  1.0a 8.6  0.5a NS
t-test P 50.001 50.001 50.001
Npb BNCs 12 nM 11.5  1.0a 12.4  1.7a 14.3  1.5a NS
120 nM 7.0  0.8a 6.0  0.6a 9.7  1.8a NS
t-test P 50.001 0.004 0.033
NBud BNCs 12 nM 31.4  2.0a 35.4  4.1a 36.7  3.1a NS
120 nM 16.5  1.8a 25.7  2.6b 20.3  2.2a,b 0.021
t-test P 50.001 0.018 50.001
BRCA2
NDI 12 nM 1.24  0.02a 1.31  0.02b 1.30  0.02b 0.009
120 nM 1.31  0.02a 1.38  0.02a,b 1.43  0.02b 0.001
t-test P 0.003 0.004 50.001
% Apoptotic 12 nM 12.1  0.8a 14.6  0.7a,b 15.4  1.0b 0.018
120 nM 14.6  1.0a 14.8  0.8a 16.2  0.9a NS
t-test P 0.011 NS NS
% Necrotic 12 nM 10.5  1.0a 11.3  0.9a 12.4  0.9a NS
120 nM 8.9  0.7a 9.6  0.5a,b 11.7  0.8b 0.019
t-test P 0.051 0.068 NS
MNed BNCs 12 nM 19.3  1.1a 19.3  1.3a 20.1  1.3a NS
120 nM 8.2  0.7a 10.3  1.0b 7.7  0.5a 0.045
t-test P 50.001 50.001 50.001
Npb BNCs 12 nM 18.0  2.6a 12.1  1.2b 11.7  1.3b 0.019
120 nM 7.9  1.0a,b 9.7  1.6a 5.7  0.5b 0.054
t-test P 0.001 NS 50.001
NBud BNCs 12 nM 32.9  2.6a 32.5  3.2a 32.0  3.3a NS
120 nM 20.6  2.4a 18.9  2.1a 17.0  2.9a NS
t-test P 50.001 50.001 50.001
Groups in one row that do not share the same superscript letter are significantly different from each other (P50.05). t-Test P values refer to companson of
12 nM and 120 nM FA cultures.
NS, not significant;
Data adjusted for age;
Data adjusted for age and BMI.
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impact of FA concentration (P 5 0.0001), BRCA2 carrier
status (P ¼ 0.0002) and BRCA2 breast cancer status (P ¼
0.0069) on adjusted viable cell growth, but no interaction
between these variables was observed. The percentage of
variation in cell growth that could be explained by the concen-
tration of FA ranged between 45 and 59%, whereas BRCA2
breast cancer status and BRCA2 carrier status explained 4.9 and
8.5% of variation, respectively (Table V).
NDI
NDI tended to be decreased in BRCA1 mutation carriers
relative to controls (P 5 0.05). In contrast, NDI of BRCA2
mutation carriers tended to be increased compared with con-
trols (P 5 0.01). NDI was significantly increased in 120 nM
FA relative to 12 nM FA in all groups (paired t-test P50.05)
except for BRCA1 mutation carriers without breast cancer.
The effect of FA concentration accounted for 25–35% of the
total variation (two-way ANOVA P50.0001) compared with
BRCA1 and BRCA2 germline mutation and breast cancer
status in the BRCA2 group, which accounted for 7, 20 and
8% of the variance (two-way ANOVA P50.01), respectively.
No interaction between FA and these parameters was
observed.
Apoptosis and necrosis
There was no difference in BRCA1 groups with respect to
apoptotic and necrotic cell frequency, but FA deficiency
tended to marginally increase necrotic cell frequency in
BRCA1 carriers without cancer (P ¼ 0.05). In contrast,
BRCA2 mutation carriers with breast cancer tended to have
a higher apoptotic and necrotic cell frequency relative to
BRCA2 carriers without breast cancer and non-carrier controls,
with significant differences between BRCA2 carriers with
breast cancer and BRCA2 controls for apoptosis at 12 nM FA
(P¼ 0.016) and necrosis at 120 nM FA (P¼ 0.021). Apoptosis
was not affected by FA concentration in the BRCA1 group.
BRCA2 carrier and breast cancer status affected apoptosis
frequency significantly, explaining 8.4% (two-way ANOVA
P ¼ 0.0192) and 8.0% (two-way ANOVA P ¼ 0.0257) of the
variance, respectively. Cancer status explained 7.4 and 10.3%
of the necrosis variance in BRCA1 and BRCA2 mutation car-
riers, respectively (P50.05). FA contributed between 6.6 and
7.4% of the necrosis variance in the BRCA1 group but had no
significant impact in the BRCA2 group.
MNed BNCs
MNed BNC frequency did not differ significantly between
controls, mutation carriers without breast cancer and those
with breast cancer in the BRCA1 group (in low as well as
high FA culture medium). The same observation was made in
the BRCA2 group for low FA culture medium but in the
120 nM culture medium MNed BNC frequency was signific-
antly elevated in the mutation carriers without cancer. There
was no significant difference in the percentage of reduction in
MNed BNCs in 120 nM cultures with respect to 12 nM in both
BRCA1 and BRCA2 mutation carriers (with or without breast
cancer) relative to their respective controls (data not shown).
Two-way ANOVA indicated that only FA concentration
influenced MNed BNC frequency significantly, accounting
for 70–75% of the variance (P50.0001) (Table V).
Npb BNCs
The frequency of Npb BNCs tended to be increased in BRCA1
mutation carriers with cancer but the differences relative to the
other groups were not statistically significant. In contrast,
BRCA2 mutation carriers (with or without cancer) had a sig-
nificant decreased frequency of Npb BNCs in 12 nM FA
cultures compared with controls (P 5 0.05); however, this
difference was less evident in 120 nM FA. FA deficiency
increased Npb BNC frequency in both BRCA1 and BRCA2
groups (P 50.05). However, the percentage decrease in Npb
BNC frequency in 120 nM relative to 12 nM FA cultures was
not significantly different for BRCA1 and BRCA2 mutation
carriers (with and without cancer) relative to controls (data
not shown). FA concentration was the most significant factor
affecting Npb BNC frequency, explaining 21–30% of the
variance (P 5 0.0001). The effect of BRCA2 carrier status
and breast cancer status (in both BRCA1 and BRCA2 mutation
carriers) on Npb BNC frequency was smaller, contributing
5.6% (P ¼ 0.022), 6.8% (P ¼ 0.015) and 6.7% (P ¼ 0.021)
of the variance, respectively. A significant interaction was
observed between FA and BRCA2 carrier status (P ¼ 0.026),
accounting for 5.3% of the variance.
NBud BNCs
The frequency of NBud BNCs tended to be increased in
BRCA1 mutation carriers relative to controls, with signifi-
cance for this effect observed in 120 nM FA cultures (P ¼
0.015). In contrast, BRCA2 mutation did not have a significant
impact on frequency of NBud BNCs compared with controls.


















Viable cell growth (day 9) 50.2 0.3 44.8 1.0 58.5 8.5 58.7 4.9
NDI 33.4 7.2 34.6 1.2 25.0 19.8 34.6 7.8
% Apoptotic 1.5 0.0 2.8 0.1 5.5 8.4 2.7 8.0
% Necrotic 7.4 1.9 6.6 7.4 5.6 5.9 3.9 10.3
MNed BNCs 74.8 0.2 72.9 0.3 69.6 0.3 71.7 0.2
Npb BNCs 22.6 2.7 20.9 6.8 30.1a, 5.6a, 24.4 6.7
NBud BNCs 32.0 6.2 33.7 2.2 25.4 0.9 28.4 0.1
Result of two-way ANOVA analysis.
P 5 0.05, P 5 0.01, P 5 0.001, P 5 0.0001.
aInteraction between these two factors explained 5.3% of the variance (P 5 0.05).
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The decrease in NBud BNC frequency observed after increas-
ing the FA concentration in the cultures from 12 to 120 nM did
not significantly differ between BRCA2mutation carriers (with
and without breast cancer) relative to controls (data not
shown). However, the percentage by which NBud BNC fre-
quency was reduced in unaffected BRCA1 carriers was signi-
ficantly less than the decrease observed in controls (data not
shown; P ¼ 0.027). FA concentration was the main determin-
ant of NBud BNC frequency, explaining between 25 and 34%
of the variance compared with 6.2 and 0.9% contributed by
BRCA1 or BRCA2 mutation carrier status, respectively
(Table V).
Discussion
The results of this study indicate that BRCA1 and BRCA2
germline mutation carriers, with or without breast cancer,
neither exhibit a marked difference in chromosome instability
relative to controls nor appear to be abnormally sensitive
towards chromosome damage induced by FA deficiency. It is
evident from these results that moderate FA deficiency has a
much stronger impact on cell growth and chromosomal stabil-
ity than BRCA1 or BRCA2 mutation and/or breast cancer
status. The observed incremental effect of 12 nM FA on
MNed BNCs, Npb BNCs and NBud BNCs is in agreement
with those of our previous studies (33,34,42).
The apparent lack of an aggravating effect of BRCA1 or
BRCA2 mutation on base-line genome damage seems surpris-
ing because BRCA1 is required for homologous recombination
repair (28), transcription-coupled repair (29) and possibly non-
homologous end joining (30), and BRCA2 plays an important
role in homologous recombination repair (31). Upon DNA
damage BRCA1 activates p21 expression which results in the
arrest of the cell cycle to allow DNA damage to be repaired
(43,44). Mutations in BRCA1 affect the G2/M cell cycle
checkpoint and mitotic spindle formation and induce centro-
some amplification, and reduced BRCA1 expression prevents
DNA damage-induced mitotic exit delay, which does not
appear to explain the reduced NDI in BRCA1mutation carriers
in our study unless these events cause fewer cells to undergo
further mitoses after the initial mitotic mishap (45). BRCA2
deficient cells are reported to show decreased levels of DNA
repair, an increased frequency of aneuploidy, chromosome
aberrations, micronuclei and centrosomes together with
decreased cell proliferation, the latter being in agreement
with our observation of reduced cell growth in BRCA2 muta-
tion carriers (46–48).
Cell growth of BRCA2, but not of BRCA1, mutation carrier
cells was reduced in our study; however, the percentage reduc-
tion in growth caused by FA deficiency did not differ between
BRCA1 or BRCA2 mutation carriers and non-carrier controls.
This indicates that although BRCA2 mutation carriers exhibit
reduced cell growth relative to controls they were not more
sensitive to the effect of folate depletion on cell growth. How-
ever, BRCA2 carriers showed increased NDI with decreased
cell growth, which seems counterintuitive. Increased NDI in
BRCA2 germline mutation carriers could be due to a defect
in cytokinesis that may have increased sensitivity to the
cytokinesis-blocking action of cytochalasin-B. Daniels et al.
(49) recently reported that targeted gene disruption of BRCA2
or reduced transcription of BRCA2 by RNA interference
delays or prevents cytokinesis in mammalian cells causing an
accumulation of binucleated cells in culture. It is therefore
possible that, in our study, the number of binucleated
BRCA2 mutant cells increased during passage of the cells
in culture and that the induced block in cytokinesis by
cytochalasin-B further enhanced this effect resulting in an
unexpectedly high NDI relative to controls. An extended
delay in cytokinesis may also explain why nucleoplasmic
bridges tended to be reduced in BRCA2 mutation carriers
because this may have allowed more time for the bridges to
break prior to cell harvesting. Whether results of BRCA gene
disruption or gene expression knockdown studies in cell lines
are relevant to normal cells of BRCA mutation carriers with
only a single defective copy remains uncertain; however, they
may reflect the situation that may emerge if a second mutation
in the residual normal gene is acquired due to a genotoxic
event. Further research is required to verify these possible
explanations.
In contrast to previous mutagen and/or clastogen-sensitivity
studies in Go-treated peripheral blood lymphocytes (cultured
for 3 days) from BRCA1 and BRCA2 mutation carriers using
the micronucleus assay (32,33,50,51), no significant effect was
observed in our study with regard to FA-deficiency induction
of micronuclei following 9-day culture. Baeyens et al. (52)
reported a lack of radiation-sensitivity, measured by the micro-
nucleus assay, after long-term culture (interleukin-2 cultures)
of lymphocytes from healthy individuals and breast cancer
patients. This could be explained by either a lack of sensitivity
to DNA damage induced in the G1-, S- or G2-phases of the cell
cycle or improved DNA repair in long-term in vitro cultures
due to optimal supply of other micronutrients required for
DNA repair (e.g. magnesium, niacin) which may have been
suboptimal in vivo. Long-term cultures are necessary to
observe the effect of folate deficiency on genome damage
(35); however, it is possible that the otherwise optimal nutri-
tional status in long-term cultures may have altered the impact
of BRCA1 and BRCA2 germline mutation causing the anticip-
ated increased genome instability in BRCA1 and BRCA2muta-
tion carriers to become undetectable. It may also be that the
effect of a mutant copy of the BRCA1 or BRCA2 gene only
becomes evident in Go because at this stage of the cell cycle
fewer DNA repair genes are expressed and repair capacity is
already somewhat compromised; however, the effect of folate
deficiency is likely to manifest itself during the cell cycle
because it is during S-phase that uracil is incorporated into
DNA. An alternative explanation is that the BRCA1 and
BRCA2 genes may not be involved in the repair of DNA
lesions induced by folate deficiency possibly because the
type of double-strand breaks in DNA that might result from
simultaneous excision of uracil (in close proximity) on oppos-
ite strands of DNA may not be a substrate of homologous
recombinational repair. In fact, it was recently shown by
gene expression array analysis that folate deficiency did not
induce expression of genes involved in DNA double-strand
break repair (53). Therefore, although experiments by Dianov
et al. (8) indicated that simultaneous excision of uracil on
opposite strands of DNA within 12 bases of each other leads
to formation of a double-strand break in plasmid DNA, it
remains unclear whether folate deficiency-induced uracil
incorporation leads to double-strand DNA breaks in human
cells.
It was hypothesized that those BRCA1 and BRCA2 mutation
carriers who develop breast cancer may exhibit a higher level
of chromosomal instability compared with carriers without
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cancer. Our results did not support this hypothesis and further-
more show that those who develop breast cancer are not more
susceptible to the genome damaging effects of folate defi-
ciency either. This may imply that other dietary/lifestyle fac-
tors, such as excessive alcohol intake, may be more important
in breast cancer aetiology. Alternatively, micronutrient defi-
ciencies that may have been extant in vivo may have been
corrected or masked by the micronutrient composition of the
culture medium, which is supra-physiological for
certain micronutrients, such as riboflavin and methionine,
and deficient for other micronutrients, such as natural antiox-
idant phenolic compounds and selenium (34). The possibility
that altered nutrient status could modify DNA repair defi-
ciency phenotype is supported by a recent study showing that
dietary supplementation with selenium corrected the mutagen-
sensitivity phenotype of BRCA1 mutation carriers (54).
It is reasonable to consider the possibility that experimental
outcomes might have been affected by certain weaknesses
in the study design. We cannot entirely exclude the possibility
that previous exposure to chemotherapy and/or radiotherapy in
the breast cancer patients may have up-regulated DNA repair
response mechanisms or altered chromosome instability in
lymphocytes; however, this seems unlikely because virtually
all participants with cancer completed chemotherapy and/or
radiotherapy at least 6 months prior to sample collection and
there was no evidence of altered genome instability in the
cancer cases relative to controls. Those with cancer may
have modified their diet post-diagnosis, which may have
impacted on the in vivo nutrient status of the cells; however,
our analysis of plasma micronutrients (folate, vitamin B12
and selenium) does not suggest marked dietary differences
between groups (data not shown). Perhaps, the use of culture
medium with physiological levels of micronutrients reflecting
in vivo status should be considered because this strategy may
prevent the possibility of masking gene–nutrient interaction
that may be operational in vivo. Another point to consider was
that the BRCA1 and BRCA2 mutation profiles of the carriers,
with or without breast cancer, were not perfectly matched;
however, the mutations in the groups studied are known patho-
logical mutations, with the exception of the 4486G4T variant
in BRCA2, for which pathological effects remain uncertain.
However, there are several other DNA repair and folate
metabolism genes that could impact on genome stability and
it is impossible to control for differences in genotype across a
host of genes. Nevertheless, the study could be improved by
substantially increasing the size of the cohort so that better
matching of genotypes becomes increasingly possible.
It cannot be excluded that the response of mammary epithe-
lial cells to FA deficiency may be different to the response of
lymphocytes as there are no published studies on folate meta-
bolism in mammary cells. In addition, it is possible that folate
metabolism in mammary cells may be different to lympho-
cytes. Clearly it would have been ideal to use primary mam-
mary cell cultures from donors with BRCA1 and BRCA2
mutations but these cells are not readily available other than
from mastectomies. This could be a possible investigation for
the future. Therefore until comparative studies are performed
between lymphocytes and mammary epithelial cells the
relevance of our results in lymphocytes to mammary cells
in vivo or ex vivo remains questionable.
In conclusion, the results of our study on BRCA1 and
BRCA2 mutations in breast cancer families show no marked
effect of these genetic defects on chromosomal instability
under folate replete or deficient conditions. It was also demon-
strated that folate deficiency is a more important determinant
of chromosomal instability than defects in the BRCA1 and
BRCA2 genes in the breast cancer families studied. More
research is needed to determine whether these observations
can be reproduced under cell culture conditions with physio-
logical concentrations of other micronutrients involved in
DNA metabolism and strand break repair.
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